Stocks Health care PGNY
NASDAQ · Health careProgyny, Inc. (PGNY)
Progyny, Inc. brought in $1.3B of revenue over the twelve months to September 30, 2026, up 5.5% from a year earlier. Net income was $91M, a net margin of 6.8%. Operating cash flow minus capital spending left $191.8M of free cash flow in fiscal 2025. At September 30, 2026 it held $116.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Progyny, Inc.
- Net worth
- Progyny, Inc. has a market value (market cap) of $2.8B at the latest share price, and shareholders' equity of $414M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.3B (+10.4% year on year), with net income of $58.5M. Over the 12 months to September 30, 2026: revenue $1.3B, net income $91M.
- Cash flow
- In fiscal 2025 operations brought in $210.2M of cash; after $18.4M of capital spending, free cash flow was $191.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Progyny, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Progyny, Inc. does
Progyny, Inc. is registered with the SEC under industry code SIC 8090 (Services-Misc Health & Allied Services, NEC). Its shares trade on NASDAQ under the ticker PGNY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.3B | $58.5M | $0.65 | $191.8M |
| 2024 | $1.2B | $54.3M | $0.57 | $173.7M |
| 2023 | $1.1B | $62M | $0.62 | $185.2M |
| 2022 | $786.9M | $30.4M | $0.30 | $77.2M |
| 2021 | $500.6M | $65.8M | $0.66 | $23.9M |
| 2020 | $344.9M | $46.5M | $0.47 | $35.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PGNY ranks in Health care
Latest SEC filings
What Progyny, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 8.9% to $341.3M versus the same quarter last year; diluted EPS $0.32 versus $0.15.
- November 4, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.3% to $350.5M versus the same quarter last year; diluted EPS $0.34 versus $0.19.
- August 6, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- June 8, 2026Passive stake changed SCHEDULE 13G/A
- May 27, 2026
- May 26, 2026Other event 8-K
- May 8, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 1.4% to $328.5M versus the same quarter last year; diluted EPS $0.29 versus $0.17.
What is PGNY worth? A DCF from its reported cash flow
Insider trades
What the people running Progyny, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $12.9M worth of shares in the last 90 days and bought none on the open market. Most of the selling (95%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 9, 2026 | Schlanger David JExecutive Chairman, Director | Exercised options | 161,208 | $146.7K |
| November 9, 2026 | Schlanger David JExecutive Chairman, Director | Soldpre-planned (10b5-1) | 161,208 | $5.8M |
| November 9, 2026 | Anevski PeterCHIEF EXECUTIVE OFFICER, Director | Exercised options | 126,204 | $114.8K |
| November 9, 2026 | Anevski PeterCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 126,204 | $4.5M |
| November 9, 2026 | Anevski PeterCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 35,104 | $1.3M |
| November 5, 2026 | Schlanger David JExecutive Chairman, Director | Exercised options | 3,400 | $3.1K |
| November 5, 2026 | Schlanger David JExecutive Chairman, Director | Soldpre-planned (10b5-1) | 3,400 | $119.8K |
| November 5, 2026 | Anevski PeterCHIEF EXECUTIVE OFFICER, Director | Exercised options | 3,400 | $3.1K |
Who owns PGNY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 14.7% | October 27, 2026 |
| Fmr LLC13G, passive with 1 related filers | 8.9% | August 6, 2026 |
| Vanguard Portfolio Management13G, passive | 6.54% | April 29, 2026 |
| Thrivent Financial For Lutherans13G, passive | 6.3% | April 29, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 311 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 11,599,921 | -398,546 |
| Fmr LLC | 7,004,280 | +503,461 |
| Vanguard Portfolio Management LLC | 5,019,465 | -272,563 |
| Vanguard Capital Management LLC | 3,210,723 | -270,616 |
| State Street Corp | 3,022,859 | -57,434 |
| Ameriprise Financial Inc | 2,763,514 | -61,817 |
| Fort Washington Investment Advisors Inc | 2,548,164 | -145,229 |
| Geode Capital Management, LLC | 1,969,208 | -73,757 |
| Citadel Advisors LLC | 1,785,717 | new |
| Dimensional Fund Advisors LP | 1,688,670 | +115,245 |
| Soleus Capital Management, L.P. | 1,602,000 | -465,000 |
| Morgan Stanley | 1,535,897 | -751,720 |
| Wellington Management Group Llp | 1,496,633 | -790,748 |
| Disciplined Growth Investors Inc | 1,181,632 | +607,066 |
| Loomis Sayles & Co L P | 1,080,928 | +92,538 |
| Baillie Gifford & Co | 1,078,629 | -142,100 |
| Jane Street Group, LLC | 1,063,363 | +914,457 |
| Easterly Investment Partners LLC | 958,117 | +124,669 |
| Charles Schwab Investment Management Inc | 954,065 | +155,441 |
| Northern Trust Corp | 802,885 | -15,291 |
Insiders
15 insiders reported holding 1,696,419 shares in total, about $61.8M at the last price.
| Holder | Shares |
|---|---|
| Anevski PeterCHIEF EXECUTIVE OFFICER, Director | 762,468 |
| Sturmer Michael EPRESIDENT | 255,205 |
| Schlanger David JExecutive Chairman, Director | 238,462 |
| Swartz AllisonEVP, GC | 83,976 |
| Livingston Mark S.CHIEF FINANCIAL OFFICER | 70,314 |
| Cummings Melissa BChief Operating Officer | 66,496 |
| Clapp GeoffreyChief Product Officer | 59,009 |
| Park Jeffrey GDirector | 39,981 |
| Holstein Roger CDirector | 28,729 |
| Dean Lloyd HDirector | 26,519 |
Questions about PGNY
What does Progyny, Inc. do?
Progyny, Inc. is a company in the Health care sector, listed on NASDAQ as PGNY. Its shares trade on NASDAQ under the ticker PGNY.
What is Progyny, Inc.'s net worth?
Progyny, Inc. has a market value (market cap) of $2.8B at the latest share price, and shareholders' equity of $414M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Progyny, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $91M on revenue of $1.3B, a net margin of 6.8%.
How much revenue does Progyny, Inc. make?
Over the twelve months to September 30, 2026 Progyny, Inc. reported revenue of $1.3B. That is 5.5% more than a year earlier.
When did Progyny, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is Progyny, Inc.'s next earnings report?
Progyny, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PGNY with
Follow PGNY
Get an email when Progyny, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Progyny, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.